References
- [1] Chang JY. The structures and proteolytic specificities of autolysed human thrombin. Biochem J. 1986; 15;240(3):797-802.
- [2] Chapman WC, Singla N, Genyk Y, McNeil J W, Renkens K L Jr, Reynolds T C, Murphy A, Weaver F A. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007; 205(2):256-265.
- [3] Cheng CH M, Meyer-Massetti C, Kayser S R. A review of three stand-alone topical Thrombin for surgical hemostasis. Clin Ther. 2009;31(1):32-41.
- [4] Geng X, Regnier FE. Retention Model for Proteins in Reversed- Phase Liquid Chromatography, J Chrom. 1984;296:15-30.
- [5] Karlsson G. Analysis of human alpha-thrombin by hydrophobic interaction high-performance liquid chromatography. Protein Expr Purif. 2003;27(1):171-4.
- [6] Lew WK, Weaver F A. Clinical use of topical thrombin as a surgical hepostat. Biologics 2008; 2(4):593-599.
- [7] Manning, MC, Chou DK, Murphy BM, Payne RW, Katayama DS.Stability of Protein Pharmaceuticals: An update. Pharm Res.2010; 27(4):544-575.
- [8] Ortel TL, Mercel MC, Thames EH, Moore KD, Lawson JH. Immunologic Impact and Clinical Outcomes After Surgical Exposure to Bovine Thrombin. Ann Surg. 2001;233(1):88-96.
- [9] Patro SY, Freud E, Chang BS. Protein formulation and fill-finish operations. Biotechnol Annu Rev. 2002; 8:55-84.
- [10] Regan F, Taylor C. Blood transfusion medicine. Br Med J. 2002; 325:143-147.